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Ferritin is an iron-storage protein composed of different ratios of 24 light (L) and heavy (H)
subunits. The serum level of ferritin is a clinical marker of the body’s iron level. Transferrin
receptor (TFR)1 is the receptor not only for transferrin but also for H-ferritin, but how it binds
two different ligands and the blood cell types that preferentially incorporate H-ferritin remain
unknown. To address these questions, we investigated hematopoietic cell-specific ferritin
uptake by flow cytometry. Alexa Fluor 488-labeled H-ferritin was preferentially incorporated
by erythroid cells among various hematopoietic cell lines examined, and was almost exclu-
sively incorporated by bone marrow erythroblasts among human primary hematopoietic
cells of various lineages. H-ferritin uptake by erythroid cells was strongly inhibited by unla-
beled H-ferritin but was only partially inhibited by a large excess of holo-transferrin. On the
other hand, internalization of labeled holo-transferrin by these cells was not inhibited by H-
ferritin. Chinese hamster ovary cells lacking functional endogenous TFR1 but expressing
human TFR1 with a mutated RGD sequence, which is required for transferrin binding, effi-
ciently incorporated H-ferritin, indicating that TFR1 has distinct binding sites for H-ferritin
and holo-transferrin. H-ferritin uptake by these cells required a threshold level of cell surface
TFR1 expression, whereas there was no threshold for holo-transferrin uptake. The require-
ment for a threshold level of TFR1 expression can explain why among primary human
hematopoietic cells, only erythroblasts efficiently take up H-ferritin.
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Introduction
Iron is essential for a variety of biological activities such as electron transfer, RNA synthesis,
and oxygen delivery; however, excess iron can cause cellular damage by inducing the overpro-
duction of reactive oxygen species [1]. Therefore, excess intracellular iron is stored in compart-
ments in the form of ferritins, which are evolutionarily conserved from prokaryotes to plants
and vertebrates [2]. In the latter, cytoplasmic ferritin forms spherical complexes composed of
24 H and L subunits; these are encoded by different genes and have approximately 50% amino
acid sequence identity and similar 3-dimensional structures [3]. Each complex can store up to
4,500 ferric ions [4]. Only the H-subunit has ferroxidase activity for the conversion of iron
incorporated into the ferritin shell from the ferrous to the ferric form [5]. The ratio of H and L
subunits in ferritin heteropolymers varies depending on cell and tissue type; for example, the H
and L subunits are more abundant in the heart and liver, respectively [6].
Ferritin is present in serum as well as in the cell. Serum ferritin is produced mainly by mac-
rophages and hepatic cells through a non-canonical secretory pathway and its concentration
correlates with the amount of iron stored in the body [7–9]. Ferritin expression increases in
response to iron load as well as immune stimuli, and under certain inflammatory conditions,
elevated serum ferritin levels reflect macrophage activation [10, 11]. The physiological func-
tions of serum ferritin are unclear, although the H-ferritin homopolymer (HFt) was reported
to inhibit normal hematopoiesis in vitro and in vivo, an effect that is linked to its ferroxidase
activity [12–14], and can potentially suppress immune responses by modulating the functions
of dendritic cells (DCs) and by activating regulatory T cells [15]. Whether serum ferritin leaks
from iron-storing cells to perform these physiological functions is unknown.
Ferritin receptors are expressed by various cell types [16]. For example, human erythroid
precursor cells possess specific receptors that bind and internalize HFt, a process that is regu-
lated by intracellular iron status [17, 18]. T cell immunoglobulin and mucin domain (TIM)-2
and scavenger receptor class A member 5 are receptors for HFt and L-ferritin (LFt), respec-
tively, in mice [19, 20]. In humans, there is no Tim–2 ortholog although HFt receptors are
expressed by various cell types [18, 21–23].
Recently, human transferrin receptor (TFR)1 was identified as a receptor for human HFt,
despite transferrin (Tf) and ferritins having completely different molecular structures [24, 25].
The mechanism of how TFR1 mediates internalization of two different ligands, and the types
of hematopoietic cell that preferentially incorporate HFt or LFt remain unknown. To address
these questions, in this study we evaluated the capacity of various human blood cell types to
incorporate ferritins as well as the mode of HFt uptake through TFR1 by flow cytometry.
Materials and Methods
Preparation of fluorescently labeled recombinant ferritin
Human recombinant ferritin H subunit was expressed in Escherichia coli strain BL21(DE3)
(Novagen, Madison, WI, USA) and human ferritin L subunit was expressed using the pET sys-
tem (Novagen) with the primer set 5'-AGC TCC CAG ATT CGT CAG AAT–3' and 5'-GCG
AAG GAT CCT TAG TCG TGC TTG AGA GTG–3'; both proteins were purified as previously
described [26, 27] and formed HFt and LFt homopolymers. The purity and integrity of the
recombinant proteins were confirmed by sodium dodecyl sulfate gel electrophoresis under
reducing and non-reducing conditions. Iron content of synthesized HFt and LFt, and cell
lysates was measured using an atomic absorption spectrophotometer (AA–6800; Shimadzu,
Kyoto, Japan) equipped with a graphite furnace atomizer. Protein concentrations were mea-
sured with the BioRad Protein Assay kit (Hercules, CA, USA) using bovine serum albumin as
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the standard. Endotoxin levels in the ferritin preparations were< 0.001%, as determined with
the Limulus ES-II Single Test (Wako Pure Chemical Industries, Osaka, Japan). Recombinant
ferritins and human holo-Tf were labeled with Alexa Fluor 488 (AF488; Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s instructions. Iron-saturated holo-Tf (Cal-
biochem, San Diego, CA, USA) and AF488-labeled holo-Tf (Life Technologies) were used for
comparisons.
Cell culture
The human leukemia cell lines K562 [28], HEL [29], MEG–01 [30], CMK-11-5 [31], HL60
[32], NB4 [33], Jurkat [34], Reh [35], and THP–1 [36] were obtained from the Japanese Collec-
tion of Research Bioresources Cell Bank and maintained in Roswell Park Memorial Institute
1640 medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) at 37°C
in a humidified atmosphere of 5% CO2, unless otherwise indicated. The erythropoietin-
dependent erythroid cell line UT–7/Epo was kindly provided by Dr. Norio Komatsu and main-
tained in the same medium supplemented with 10% FBS and 1 U/ml recombinant human
erythropoietin (Kyowa Hakko Kirin, Tokyo, Japan) [37]. The Chinese hamster ovary cell line
CHO-TRVb, which lacks functional TFR1, was kindly provided by Dr. Timothy McGraw and
maintained in Ham’s F12 nutrient mixture (Life Technologies) supplemented with 5% FBS
[38].
Patient samples
Peripheral blood and bone marrow (BM) cells from healthy donors (n = 5 and 3, respectively)
and BM cells from myelodysplastic syndrome (MDS) patients (n = 4) were obtained with writ-
ten, informed consent from the donors. The Institutional Review Board of the Graduate School
of Medicine of Kyoto University approved the study protocol, which was carried out in accor-
dance with the Helsinki Declaration.
Confocal microscopy
K562 cells were incubated with 110 nM AF488-labeled recombinant human HFt homopolymer
or 550 nM AF488-labeled human holo-Tf for 1 h at 37°C followed by incubation with Hoechst
33342 (Dojindo, Kumamoto, Japan). After washing with phosphate-buffered saline, cells were
analyzed by confocal laser scanning fluorescence microscopy (Digital Eclipse C1; Nikon,
Tokyo, Japan).
Ligand binding and uptake assays
Cells were incubated with AF488-labeled ligands on ice (for the binding assay) or at 37°C (for
the uptake assay) for 60 min, unless otherwise indicated, and analyzed using a FACSCalibur
flow cytometer and CellQuest software (BD Biosciences, Franklin Lakes, NJ, USA). The ratio
of mean fluorescence intensity (MFI) of AF488-labeled ligand-treated cells to that of untreated
cells was used as an indicator of fluorescently labeled ligand binding or uptake. Competitive
inhibition assays were performed using a 20-fold excess of unlabeled ligand unless otherwise
indicated. Experiments were repeated at least three times to confirm reproducibility.
Fluorescence-activated cell sorting
To determine the size of peripheral blood leukocyte and BM nucleated cell populations, cells
were labeled with the following antibodies against human cell surface markers: anti-human
cluster of differentiation (CD)235a-phycoerythrin (PE), CD14-PE-cyanin 5, CD16-PE,
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CD20-PE, CD203c-PE, CD3-PE-cyanin 5, CD4-PE-cyanin 5, CD4-PE-cyanin 7, CD8-PE-cya-
nin 5, and CD56-PE (all from BioLegend, San Diego, CA, USA); CD71-PE-cyanin 5, CD3-PE,
and CD11c-PE (all from BD Biosciences); and CD141-allophycocyanin (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). The total lymphocyte population was determined from forward
and side scatter, and CD4+ and CD8+ T cells, natural killer (NK) cells, and B cells were sepa-
rated into CD3+/CD4+, CD3+/CD8+, CD56+/CD3−, and CD20+ populations, respectively.
The monocyte population was determined from forward and side scatter and by CD14 expres-
sion. The granulocyte population was gated by forward and side scatter, and neutrophils and
eosinophils were separated according to CD16 expression (CD16+ and CD16−, respectively).
Basophils were isolated as the CD203c+ population. Plasmacytoid DCs, CD1c+ myeloid DCs,
and CD141high myeloid DCs were isolated from peripheral blood mononuclear cells on a
FACSAriaII cell sorter as previously described [39]. Erythroid cells present in the BM cell pop-
ulation were gated according to CD235 and CD71 (TFR1) expression.
Mutagenesis and cell transfection
We used a KOD-Plus-Mutagenesis kit (Toyobo, Osaka, Japan) to introduce point mutations
into the human TFR1 cDNA sequence to generate the R646H and G647A mutants. A FLAG-
tag was also inserted at the 5'-end of the cDNAs, which were subcloned into pcDNA3.1 (Life
Technologies). Stably transfected CHO-TRVb cell lines expressing either FLAG-tagged human
wild-type or mutant TFR1 were established based on a published protocol [40].
Statistical analysis
Data are presented as mean ± SE. Differences between test and control values were assessed
with a paired t- test, and P< 0.05 was considered statistically significant.
Results
H-ferritin incorporation by K562 cells
Since human myeloid leukemia K562 cells express ferritin receptors [21], we used these cells to
determine experimental conditions. The iron content of our recombinant human HFt and LFt
was approximately 40 and 4 atoms, respectively, for each ferritin 24-mer.
We first evaluated the binding of HFt to cells, which were incubated with various concentra-
tions of AF488-labeled HFt for 60 min at 0°C and analyzed by flow cytometry after fixation.
HFt binding, as determined by the MFI ratio, increased in a dose-dependent manner, reaching
near-saturation at 110 nM (Fig 1A). We chose a standard concentration of 11 nM (approxi-
mately 5,000 ng/ml) of AF488-labeled ferritin for subsequent experiments since it is an achiev-
able concentration in sera from patients with severe iron overload [41, 42]. AF488-labeled HFt
binding was almost completely inhibited by 100-fold excess of unlabeled HFt, indicating that
this binding occurred through specific machinery (Fig 1B).
It was previously reported that HFt is rapidly incorporated into cells after binding to TFR1
and then transferred to endosomes and lysosomes; intracellular distribution of incorporated
HFt differed from that of holo-Tf [24]. Consistent with this report, at 37°C, AF488-labeled HFt
was rapidly incorporated by cells and visible as cytoplasmic puncta, in contrast to the more dif-
fuse distribution of holo-Tf (Fig 1C). Thus, we confirmed that HFt does not remain at the
plasma membrane but it is immediately internalized at 37°C.
We next examined the uptake of AF488-labeled ligands by these cells at 37°C. The MFI
ratio increased in a dose-dependent manner; the increase was steep at concentrations<22 nM
and more gradual at higher concentrations (up to 220 nM) (Fig 1D). For comparison, we also
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examined cellular holo-Tf uptake. Similar to HFt uptake, the incorporation increased in a
dose-dependent manner with a steep increase at concentrations<62 nM, and a more gradual
increase at higher concentrations (up to 1250 nM) (Fig 1E). The time course of HFt uptake
showed that the MFI ratio increased sharply until 5 min (rapid phase), and which the increase
was more gradual. Near-constant HFt uptake was observed between 30 min and 120 min (slow
phase; Fig 1F). A similar pattern was observed in the time course of holo-Tf uptake (Fig 1G).
Based on these results, we chose 60 min as the standard incubation time for ligand uptake
assays. A competition assay was carried out using unlabeled ligand to determine whether HFt
uptake was mediated by specific or non-specific mechanisms. Unlabeled HFt inhibited
AF488-labeled HFt uptake in a concentration-dependent manner. In the presence of a 50-fold
excess of unlabeled ligand, AF488-labeled HFt uptake was reduced to 20% of that in the
absence of unlabeled ligand, indicating that approximately 80% of HFt uptake by K562 cells
was mediated by a specific mechanism (Fig 1H).
Ferritin uptake by hematopoietic cell lines
We evaluated the uptake of AF488-labeled human HFt and LFt by various human leukemia
and lymphoma cell lines. Since TFR1 is the receptor for human HFt, we also examined the
uptake of AF488-labeled human holo-Tf. All cell lines incorporated AF488-human holo-Tf,
which was inhibited by unlabeled holo-Tf (Fig 2A). In contrast, K562, HEL, UT–7/EPO,
MEG–01, CMK-11-5, HL60, and Jurkat cells preferentially incorporated HFt (MFI ratios of
9–59), whereas NB4 cells preferentially took up LFt (Fig 2A). Reh pre-B leukemia cells and
THP–1 monocytic cells internalized modest amounts of HFt and LFt (MFI ratios< 4). Inter-
estingly, strong HFt uptake (MFI ratios>30) was confined to cell lines exhibiting erythroid
and megakaryocytic properties (i.e., HEL, UT–7/EPO, MEG–01, and CMK-11-5). HFt uptake
by all cells was competitively but partially inhibited by a 20-fold excess of unlabeled ligand. In
contrast, a large excess of unlabeled LFt did not prevent labeled LFt incorporation, suggesting a
non-specific uptake mechanism. When we plotted these cell lines by their MFI-ratios of HFt
uptake (y) and holo-Tf uptake (x), a linear relationship was observed (calculated best-fit curve,
y = 0.0756x1.3, R2 = 0.9738) (Fig 2B), indicating that these ligands are internalized via a com-
mon pathway that is probably mediated by TFR1 [24]. These data also indicated that HFt
uptake required much higher TFR1 expression than holo-Tf uptake.
Ferritin uptake by primary human leukocytes
To determine whether the above observations are representative of ferritin uptake in a physio-
logical context, we analyzed the incorporation of human holo-Tf, HFt, and LFt by various
types of peripheral human blood cells harvested from healthy donors, which were incubated
Fig 1. H-ferritin uptake by K562 cells. (A) Confocal micrographs of AF488-labeled H-ferritin (HFt) and holo-
transferrin (Tf). Cells were incubated with 50 μg/ml (110 nM) AF488-labeled human recombinant HFt or
50 μg/ml (625 nM) holo-Tf for 1 h at 37°C. Images are representative results of three independent
experiments. (B) Analysis of HFt binding to K562 cells. Cells were incubated with indicated concentrations of
AF488-labeled HFt for 60 min on ice, and HFt binding was analyzed by flow cytometry. (C) Competitive
inhibition of HFt uptake by K562 cells. Cells were incubated with 11 nM AF488-labeled ferritin in the presence
or absence of a 100-fold excess of unlabeled HFt for 60 min on ice, followed by flow cytometric analysis. (D,
E) Dose-dependency of HFt and holo-Tf uptake. Cells were incubated with indicated concentrations of
AF488-labeled HFt or holo-Tf for 60 min at 37°C, and incorporation of these ligands was analyzed by flow
cytometry. (F, G) Time-course of HFt and holo-Tf uptake by K562 cells. Cells were incubated with 11 nM
AF488-labeled HFt or 62 nM holo-Tf for indicated times, and incorporation of these ligands was analyzed by
flow cytometry. (H) Competition of AF488-labeled HFt uptake with unlabeled ligand. Cells were incubated
with 11 nM AF488-labeled HFt and indicated concentrations of unlabeled HFt. (B–H) Data represent the
means ± standard errors of three independent experiments.
doi:10.1371/journal.pone.0139915.g001
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with AF488-labeled ligands and separated into CD4+ and CD8+ T cell, NK cell, B cell, mono-
cyte, neutrophil, eosinophil, basophil, plasmacytoid DC, CD1c+ myeloid DC, and CD141+
myeloid DC populations based on forward and side scatter using antibodies against specific
cell surface markers. Modest levels of holo-Tf were incorporated by monocytes, plasmacytoid
DCs, and CD141+ myeloid DCs. The uptake of holo-Tf by DCs but not by monocytes was com-
petitively inhibited by unlabeled ligand (Fig 3A). With the exception of monocytes, very little
HFt was incorporated by these cells. Modest levels of AF488-labeled HFt were incorporated by
monocytes, but the incorporation was not inhibited in the presence of excess unlabeled HFt. In
contrast, high levels of LFt were taken up by B cells and monocytes, and to lesser degrees by
CD1+ and CD141+ myeloid DCs; this was not blocked in the presence of excess unlabeled LFt,
indicating that the uptake was non-specific (Fig 3A).
We also examined AF488-labeled ferritin internalization by normal human BM cells. Eryth-
roblasts were separated as a CD235a+/CD71+ population, and based on side scatter, the
remaining cells were separated into lymphocytes, monocytes, and granulocytic cells. Holo-Tf
and HFt were taken up by erythroblasts; this was inhibited by a 20-fold excess of unlabeled
ligand, suggesting a specific uptake mechanism (Fig 3B). HFt uptake was higher by erythro-
blasts than by HL60, Jurkat or K562 cells, which showed comparable levels of holo-Tf uptake
(Fig 2A and the red dot in Fig 2B). Monocytes also incorporated holo-Tf and HFt, although
their MFI ratios (5.6 and 3.8, respectively) were far lower than those of erythroblasts (36 and
41, respectively). Lymphocytes and granulocytic cells incorporated very little of either ligand
(MFI ratios< 2).
We tested HFt uptake by BM cells from four MDS patients and found variable cell surface
expression levels of TFR1 (Fig 3C). HFt uptake was reduced in samples from two patients with
decreased levels of cell-surface TFR1 (Fig 3C, Patient 2).
Effects of cellular iron status on H-ferritin uptake by erythroid cells
To characterize the mechanism of HFt uptake by erythroid cells, we used UT–7/EPO erythro-
leukemia cell lines that exhibited enhanced HFt incorporation relative to K562 cells. Since
TFR1 expression is downregulated in response to excess levels of iron and is upregulated when
iron is chelated [43], we evaluated whether cellular iron status influences HFt uptake. Iron con-
tent of the UT–7/EPO cell lysate was approximately 3.2±0.3 μmol/g, and it became 6.0±0.3, 9.4
±0.2 and 2.0±0.1 μmol/g after 24 h incubation with 50 μM ferric ammonium citrate (FAC),
100 μM FAC and 10 μMDFO, respectively. As expected, cell surface TFR1 (CD71) expression
in UT–7/EPO was slightly reduced after a 24-h pre-incubation with FAC, and was increased by
pre-incubation with desferrioxamine (DFO) (Fig 4A, upper panel). HFt uptake was reduced by
pre-incubation with FAC in a dose-dependent manner and was enhanced by pre-incubation
with DFO (Fig 4A, lower panel). Therefore, cellular iron status influences the incorporation
of HFt by erythroid cells, providing evidence that TFR1 is an HFt receptor [24]. In these
Fig 2. Analysis of H-ferritin and holo-transferrin uptake by hematopoietic cell lines. (A) Uptake of
AF488-labeled human holo-transferrin (Tf), H-ferritin (HFt), and L-ferritin (LFt). Cells were incubated with
AF488-labeled ferritins (11 nM) or Tf (62 nM) for 60 min and analyzed by flow cytometry. The MFI ratio was
defined as the MFI of cells treated with fluorescence-labeled ligand divided by the MFI of untreated cells.
Filled columns denote the results of competition experiments using a 20-fold excess of unlabeled cognate
ligand. Graphs for NB4, Reh, and THP–1 cell lines are shown on a larger scale in the in the enclosed areas.
Data represent the mean ± standard error of three independent experiments. (B) Relationship between HFt
and holo-Tf uptake. Cell lines shown in (A) are shown as blue dots by their MFI ratios for HFt and holo-Tf
uptake in a scatter plot (Spearman’s coefficient, ρ = 0.95; P < 0.0001). A red dot in this plot represents the
position of human bone marrow erythroblasts shown in Fig 3B.
doi:10.1371/journal.pone.0139915.g002
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experiments, we noticed that changes in HFt uptake were larger than those in TFR1 expression.
Similar results were obtained using HEL erythroleukemia cells (Fig 4B).
Competition assays for H-ferritin and holo-transferrin uptake by erythroid
cells
To determine whether holo-Tf and HFt bind to the same or to different sites on TFR1, we per-
formed competition assays using unlabeled ligand. AF488-labeled HFt incorporation by UT–7/
EPO cells was strongly inhibited by unlabeled HFt in a dose-dependent manner but was only
partially inhibited by a large excess of unlabeled holo-Tf (Fig 5A, upper panel). In contrast,
internalization of AF488-labeled human holo-Tf by the cells was effectively inhibited by
Fig 3. H-ferritin uptake by primary human hematopoietic cells. (A) Uptake of AF488-labeled human holo-
transferrin (Tf), H-ferritin (HFt), and L-ferritin (LFt) by peripheral blood leukocytes. (B) Uptake of
AF488-labeled Tf, HFt, and LFt by normal nucleated human BM cells. In (A) and (B), cells were incubated
with AF488-labeled ferritins (11 nM) or Tf (62 nM) for 60 min and analyzed by flow cytometry. The MFI ratio
was defined as the MFI of cells treated with fluorescence-labeled ligand divided by the MFI of untreated cells.
Filled columns denote the results of competition experiments using a 20-fold excess of unlabeled cognate
ligand. Data represent the mean ± standard error of three independent experiments. (C) Representative
results of HFt uptake by erythroid cells fromMDS patients. CD235+ erythroid cells from Patient 1 expressed
close to normal levels of CD71 (TFR1) and efficiently incorporated HFt, whereas cells from Patient 2
expressed relatively low levels of TFR1 and incorporated less HFt as compared to cells from normal subjects.
Solid lines represent AF488-labeled ligand uptake and shaded areas represent controls.
doi:10.1371/journal.pone.0139915.g003
Fig 4. HFt uptake by erythroid cells in various iron statuses. (A, B) UT7/EPO and HEL cells were incubated with indicated concentrations of FAC or DFO
for 24 h before flow cytometry analysis of CD71 (TFR1) expression (upper panels) and HFt (HFt) uptake (lower panels). MFI values relative to those of
controls were calculated for each experiment; the results represent the mean ± standard error of at least three independent experiments. *P <0.05,
**P <0.01; n.s., not significant.
doi:10.1371/journal.pone.0139915.g004
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unlabeled holo-Tf in a dose-dependent manner but was not inhibited by unlabeled HFt (Fig
5A, lower panel). Unexpectedly, unlabeled HFt enhanced holo-Tf uptake by cells. Similar
results were obtained using HEL cells (Fig 5B). These results suggest that TFR1 mediates the
uptake of Tf and HFt, which bind to different sites on TFR1.
H-ferritin uptake by wild-type and mutant TFR1
We established CHO-TRVb cell lines that express wild-type or mutant forms of human TFR1
and analyzed their uptake of holo-Tf and H- and L-ferritins. We introduced mutations in the
RGD sequence (R646H/G647A) of TFR1, which is essential for binding Tf [44]. Consistent
with a previous report, TFR1-deficient CHO-TRVb cells did not incorporate HFt, in contrast
to CHO-TRVb cells stably transfected with wild-type human TFR1 (Fig 6A, left) [24].
CHO-TRVb cells expressing TFR2 also failed to incorporate HFt (Fig 6A, right). The presence
of R646H/G647A mutations in TFR1 markedly reduced holo-Tf but not HFt uptake (Fig 6A,
third and fourth panels from the left).
CHO-TRVb cell lines expressing different levels of TFR1 revealed that HFt incorporation
was positively correlated with increased TFR1 expression (Fig 6B). The TFR1high cells incorpo-
rated a large amount of A488-labeled HFt, whereas only modest incorporation was observed
for TFR1moderate cells, indicating that HFt uptake required high levels of TFR1 expression.
Uptake of AF488-labeled HFt was competitively inhibited by unlabeled HFt, confirming that
Fig 5. Effect of H-ferritin on holo-Tf uptake by erythroid cells. (A, B) Competition assays of the TFR1 ligands holo-transferrin (Tf) and H-ferritin (HFt).
UT7/EPO (A) or HEL (B) cells were incubated with AF488-labeled holo-Tf or HFt along with the indicated concentrations of unlabeled ligand, and cellular
uptake of AF488-labeled ligand was analyzed. Data represent the mean ± standard error of three independent experiments. *P <0.05, **P <0.01; n.s., not
significant.
doi:10.1371/journal.pone.0139915.g005
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uptake occurred through specific machinery (Fig 6B). In these wild-type TFR1-expressing
CHO-TRVb cell clones, the cell-surface expression of TFR1 in individual cells was highly vari-
able, and was linearly related to holo-Tf uptake (Fig 6C, upper panels). In contrast, the correla-
tion between TFR1 and HFt uptake was linear only above a threshold level of TFR1 expression
(Fig 6C, lower panels). CHO-TRVb cells expressing mutant TFR1 (R646H/G647A) did not
efficiently incorporate holo-Tf but their uptake of HFt was similar to that of cells expressing
wild-type TFR1 (Fig 6C, fourth and fifth panels from the left).
Discussion
Since the 1980s, several reports have demonstrated that different types of human blood cell
have specific HFt binding sites [18, 21–23], but the specific HFt receptor in these cells were not
identified for a long time. Recently, human TFR1 was identified as an HFt receptor that is
quickly transported to endosomes and lysosomes following TFR1-mediated endocytosis [24].
Since the binding of HFt to TFR1 was previously investigated [24], in the current study, we
focused on the mechanism of HFt uptake by cells. Analyzing ligand uptake—which includes
ligand binding to the plasma membrane, endocytosis, and intracellular trafficking—is impor-
tant for understanding the physiological roles of the ligand. We established a quantitative flow
cytometry-based method for measuring ligand uptake using AF488 and confirmed that holo-
Tf and HFt are incorporated by human cells through a TFR1-medited mechanism (Fig 1).
TFR1 is highly expressed in cells that require high levels of iron such as erythroid precur-
sors, rapidly proliferating cells, and cancer cells [45]. Accordingly, various human leukemia
and lymphoma cell lines—especially erythroid leukemia cell lines—incorporate AF488-labeled
HFt (Fig 2). We showed here that among primary human hematopoietic cells, erythroid pre-
cursor cells expressing relatively high levels of TFR1 preferentially and specifically take up HFt
(Fig 3). We detected very low levels of HFt incorporatin by immune cells such as lymphocytes
and dendritic cells (Fig 3), but previous studies have reported that ferritin has immunosuppres-
sive effects in vitro as well as in patients [15, 46, 47], indicating that immune cells also express
an HFt receptor. Cell surface TFR1 expression is low in steady-state lymphocytes; but once
activated, these cells express high levels of TFR1 [48]. These activated lymphocytes are pre-
sumed to incorporate HFt, which is supported by a previous report demonstrating that lym-
phoid cells upregulated HFt receptor expression in the presence of phytohaemagglutinin, and
that HFt inhibited the growth of phytohaemagglutinin-stimulated lymphocytes [22].
Dysplastic erythroid cells in MDS patients were reported to express relatively low levels of
TFR1 as compared to normal erythroid precursors [49]. Consistent with these observations, we
found that cell-surface TFR1 expression was lower in erythroid cells from two of our MDS
patients than in normal erythroid cells. Given that a threshold level of TFR1 expression is nec-
essary for HFt uptake, dysplastic erythroid cells expressing a low level of TFR1 may not effi-
ciently incorporate HFt (Fig 3C).
Fig 6. TFR1 expression levels required for H-ferritin uptake. (A) AF488-labeled H-ferritin (HFt) and holo-transferrin (Tf) uptake was evaluated in
CHO-TRVb cells lacking endogenous TFR1 (control) and CHO-TRVb cells expressing either wild-type or mutant human TFR1 (R646H and R646H/647A) or
wild-type human TFR2. Shaded areas represent isotype control experiments (CD71 expression) and untreated control experiments (Tf and HFt uptake). (B)
AF488-labeled holo-Tf and HFt uptake by CHO-TRVb cells expressing moderate or high levels of human TFR1. Representative histograms are shown (left
panels). Uptake of AF488-labeled ligand (solid lines), competition experiments using a 20-fold excess of unlabeled ligand (broken lines), and controls
(shaded areas) are shown. Data shown in the right panel represent the mean ± standard error. (C) Relationship between CD71 expression and HFt uptake by
CHO-TRVb cells expressing wild-type or mutant forms of human TFR1. Data from two cell lines expressing wild-type TFR1 and two expressing a mutated
form of TFR1 (R646H/647A) are shown. Right panels show a schematic representation of two different patterns of ligand uptake.
doi:10.1371/journal.pone.0139915.g006
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In the current study, we also investigated the difference between HFt uptake and holo-Tf
uptake through TFR1, and demonstrated that HFt uptake requires a threshold level of cell sur-
face TFR1 expression, in contrast to Tf uptake for which there is no threshold (Fig 6C). This
was supported by an analysis of the relationship between holo-Tf and HFt uptake by various
hematopoietic cell lines; the calculated best fit curve indicated that much higher TFR1 expres-
sion was required for HFt uptake than for holo-Tf uptake (Fig 2B). The requirement for a
threshold level of TFR1 expression can explain why only certain cell types such as erythroid
cells efficiently take up HFt, while other cell types can efficiently incorporate holo-Tf but not
HFt (Figs 2 and 3), and why changes in HFt uptake by erythroid cells were greater than changes
in TFR1 expression (Fig 4). The threshold-dependent pattern of HFt uptake may suggest that
more than one TFR1 complex is required for HFt incorporation. Primary human erythroblasts
from bone marrow showed greater efficiency of HFt uptake relative to hematopoietic cell lines
which showed comparable levels of holo-Tf uptake (Fig 2A and the red dot in Fig 2B). The rea-
son of this phenomenon is unknown, but bone marrow erythroblasts may have different distri-
bution patterns of TFR1 on the plasma membrane, they may have a co-receptor for facilitating
HFt uptake, or they may possess efficient intracellular trafficking machineries for incorporated
HFt.
TFR1 forms a homodimeric complex at the cell surface that can interact with two Tfs. The
results of our competition assays showed that HFt and Tf do not compete for TFR1-mediated
cellular uptake, indicating that the TFR1 complex has distinct binding sites for HFt and Tf.
This is supported by the fact that the RGD sequence—which is essential for holo-Tf uptake—
was not required for HFt incorporation by cells expressing TFR1 (Fig 6, panels A and C).
Unexpectedly, unlabeled HFt rather enhanced incorporation of AF488-labeled Tf by HEL cells,
suggesting that HFt facilitates holo-Tf uptake through undetermined mechanisms (Fig 5A).
There were limitations to the present study. Firstly, we used recombinant proteins synthe-
sized in bacteria that were not subjected to posttranslational modifications such as glycosyla-
tion, which may have influenced the results. Secondly, we analyzed HFt uptake only in vitro. In
mice, TIM2 serves as a HFt receptor, but there are no Tim2 orthologs in the human genome
[50]. Therefore, mechanisms of HFt uptake in mice may not reflect human serum ferritin activ-
ity. Thirdly, we are not able to separate binding and intracellular trafficking by flow cytometry
in the current study. The time course experiments of HFt and holo-Tf uptake shown in Fig 1,
panels E and F indicated that ligand uptake can be separated at least into 3 phases; the rapid
phase, gradually retarding phase, and the slow phase in which the MFI-increasing ratio
becomes constant. We assume that the rapid phase represents the ligand binding and the early
steps of endocytosis, and the following slow phase represents the rate-limiting steps in the
intracellular trafficking. Such time course experiments may be useful to dissect these steps and
to separately estimate the efficacies of these two phases of the ligand uptake process.
It was recently demonstrated that endogenous cytoplasmic HFt is transported to autopha-
gosomes through a nuclear receptor coactivator 4-mediated mechanism [51, 52]. Serum HFt
endocytosed by TFR1 may be transported to lysosomes via a similar mechanism given that the
intracellular domain of TFR1 has been shown to interact with γ-aminobutyric acid A receptor
[53], which is a potential binding partner of nuclear receptor coactivator 4 [51]. Cells may uti-
lize iron released by degraded ferritin, but it is unlikely that serum ferritin is a major source of
cellular iron [54].
In conclusion, we showed here that among human hematologic cell types, erythroid cells
preferentially incorporate HFt through a TFR1-mediated mechanism. We also showed that
TFR1 has distinct binding sites for HFt and Tf. Moreover, we showed that cellular uptake of Tf
and HFt by TFR1 differ in that only the latter depends on a threshold of level of ligand. Further
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studies are required to clarify the fate of HFt after internalization, and the roles of HFt in eryth-
ropoiesis in physiological and iron overloaded conditions.
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